2005
DOI: 10.1177/120347540500900610
|View full text |Cite
|
Sign up to set email alerts
|

Unilateral Basal Cell Carcinomas: An Unusual Entity Treated with Photodynamic Therapy

Abstract: We report a patient with unilateral basal cell carcinomas successfully treated with photodynamic therapy. This uncommon entity represents a diagnostic challenge in its inherent absence of the classic clinical and radiographic findings of nevoid basal cell carcinoma syndrome. Like nevoid basal cell carcinoma syndrome, unilateral basal cell carcinomas poses a therapeutic challenge with the sheer number of cutaneous tumors. The use of photodynamic therapy carries a proven therapeutic efficacy, a low rate of adver… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
4
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 32 publications
1
4
0
Order By: Relevance
“…Even more pronounced case of unilateral localization of multiple BCCs was described by Lane et al (8), where a 56-year-old Caucasian male presented with 14 BCCs on the left side of his body. As in the previous report, Lane et al (8) did not find any associated lesions or abnormalities. Treatment with photodynamic therapy (PDT) was effective.…”
Section: Non-syndromic Unilateral Basal Cell Carcinomas: a Case Reporsupporting
confidence: 74%
“…Even more pronounced case of unilateral localization of multiple BCCs was described by Lane et al (8), where a 56-year-old Caucasian male presented with 14 BCCs on the left side of his body. As in the previous report, Lane et al (8) did not find any associated lesions or abnormalities. Treatment with photodynamic therapy (PDT) was effective.…”
Section: Non-syndromic Unilateral Basal Cell Carcinomas: a Case Reporsupporting
confidence: 74%
“…In NBCCS, the recurrence rate was between 5% and 10% for Oseroff et al. 12 after a maximal follow‐up period of 6 years, whereas other studies on NBCCS noted no recurrence at all after a follow‐up period ranging from 4 to 10 mon 11,17,18 . Thus, a long clinical follow‐up would be necessary to detect late recurrence in our patients.…”
Section: Discussionmentioning
confidence: 61%
“…31 Blue light was also used successfully in several dermatological conditions. [32][33][34][35] We have used two in-house made lamps to examine whether there is a difference in the outcome of HAL-PDT with red and blue light and after illumination with different irradiances in five different human cancer cell lines. The following discussion is divided into three main topics: irradiance and wavelength, cell-line specific response, and apoptosis induction.…”
Section: Discussionmentioning
confidence: 99%